secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2023-08-28T23:59:59+00:00
Accession:  0001104659-23-095577
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee Therapeutics Q2 net loss $18.9M; $345M IPO funds runway into 4Q26
------------------------------------------------------------------------

- Raised $345M in upsized July IPO; cash balance $125.1M at June 30; projected runway into 4Q 2026.
- Phase 1 trial of APG777 initiated; initial safety/PK data expected mid-2024.
- Appointed Mark McKenna Chairman, Matt Batters General Counsel, Rebecca Dabora CTO.
- Net loss Q2 2023 $18.9M vs $1.8M in Q2 2022; R&D expenses rose to $13.9M.
- APG808 development candidate selected expected Q4 2023; APG990 candidate in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465923095577/0001104659-23-095577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465923095577/tm2324402d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-095577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer